A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.

Abstract

AZD9668 is a fully reversible, selective, oral inhibitor of neutrophil elastase, a protease implicated in chronic obstructive pulmonary disease (COPD). Efficacy, safety and tolerability of AZD9668 (5, 20 and 60 mg bid) were compared with placebo in a randomised, double-blind, placebo-controlled, 12-week, Phase IIb trial (NCT00949975: approved by an Investigational Review Board), in patients with symptomatic COPD receiving maintenance tiotropium. The primary endpoint was pre-bronchodilator forced expiratory volume in 1 second (FEV₁). Secondary endpoints included forced vital capacity and inspiratory capacity, peak expiratory flow, Breathlessness, Cough and Sputum Scale score, exercise capacity, quality of life (QoL), exacerbation assessments, safety and pharmacokinetics. Exploratory endpoints included inflammatory and tissue degradation biomarkers. A total of 838 patients were randomised to AZD9668 5 mg bid (212 patients), 20 mg bid (206 patients), 60 mg bid (202 patients) or placebo (218 patients). AZD9668 showed no effect on lung function, respiratory signs and symptoms, QoL or biomarkers. At end of treatment, the change in mean pre-bronchodilator FEV₁ for AZD9668 60 mg bid compared with placebo was 0.00L (95% confidence interval: -0.05, 0.04; p = 0.873). Overall, AZD9668 was well tolerated; the numbers of patients with adverse events (AEs), serious AEs and AEs leading to discontinuation were similar in each of the four study groups. AZD9668 60 mg bid showed no clinical benefit and no effect on biomarkers of inflammation or tissue degradation when added to tiotropium in patients with COPD. These results raise important questions for future investigation of anti-inflammatory and disease-modifying agents in patients with COPD.

• Authors: Claus Vogelmeier, Teresita O Aquino, Christopher D O'Brien, John Perrett, Kulasiri A Gunawardena
• Journal: COPD (COPD) Vol. 9 Issue 2 Pg. 111-20 (Apr 2012) ISSN: 1541-2563 [Electronic] England
• PMID: 22458939 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Bronchodilator Agents
• Pyridones
• Scopolamine Derivatives
• Sulfones
• N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
• Leukocyte Elastase
• Tiotropium Bromide

Topics

• Administration, Oral
• Adult
• Aged
• Aged, 80 and over
• Biomarkers (analysis)
• Bronchodilator Agents (administration & dosage, adverse effects, therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Forced Expiratory Volume (drug effects)
• Humans
• Leukocyte Elastase (antagonists & inhibitors)
• Male
• Middle Aged
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Pyridones (administration & dosage, adverse effects)
• Quality of Life
• Scopolamine Derivatives (therapeutic use)
• Spirometry
• Sulfones (administration & dosage, adverse effects)
• Tiotropium Bromide
• Treatment Outcome